Director/PDMR Shareholding
February 21, 2017 – Shire
plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by person
discharging managerial responsibilities
| 1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
| a) |
Name |
Perry Sternberg |
| 2. |
Reason for the
notification |
| a) |
Position / status |
Head of US Commercial -
PDMR |
| b) |
Initial notification /
amendment |
Initial
notification |
| 3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Shire plc |
| b) |
LEI |
54930005LQRLI2UXRQ59 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
| Identification
code |
ISIN:
US82481R1068 |
| b) |
Nature of the transaction |
Exercise of Stock
Appreciation Rights (“SARs”) in respect of 3,558 notional ADSs
awarded under the Shire Portfolio Share Plan and consequent receipt
of ADSs. (Details of related disposals of ADSs are referenced in
the sections below.) |
| c) |
Price(s)
and volume(s) |
Exercise price(s) |
Volume(s) ADSs received |
| $119.27 |
1,202 |
| d) |
Aggregated
information |
N/A
(single transaction) |
| e) |
Date of the transaction |
February 17, 2017 |
| f) |
Place of the transaction |
N/A |
| 5. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
| Identification
code |
ISIN:
US82481R1068 |
| b) |
Nature of the transaction |
Disposals
of ADSs
(Disposals marked with * are in relation to the exercise of SARs
referenced in section 4. above. Part of the proceeds of these
disposals were used to satisfy personal tax liabilities arising
from the exercise of the SARs.) |
| c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
| $180.87* |
200 |
| $180.73* |
200 |
| $180.73* |
200 |
| $180.28 |
99 |
| $180.29 |
300 |
| d) |
Aggregated
information |
Weighted average price |
Volume |
|
$180.58 |
999 |
| e) |
Date of the transaction |
February 17, 2017 |
| f) |
Place of the transaction |
NYSE (BQT) |
| 6. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
| Identification
code |
ISIN:
US82481R1068 |
| b) |
Nature of the transaction |
Disposals of ADSs in
relation to the exercise of SARs referenced in section 4. above.
Part of the proceeds of these disposals were used to satisfy
personal tax liabilities arising from the exercise of the
SARs. |
| c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
| $180.86 |
100 |
| $180.85 |
100 |
| $180.85 |
185 |
| $180.85 |
100 |
| $180.71 |
17 |
| d) |
Aggregated
information |
Weighted average price |
Volume |
| $180.85 |
502 |
| e) |
Date of the transaction |
February 17, 2017 |
| f) |
Place of the transaction |
NASDAQ |
| 7. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
| Identification
code |
ISIN:
US82481R1068 |
| b) |
Nature of the transaction |
Disposal of ADSs in
relation to the exercise of SARs referenced in section 4. above.
Part of the proceeds of this disposal were used to satisfy personal
tax liabilities arising from the exercise of the SARs. |
| c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
| $180.76 |
100 |
| d) |
Aggregated
information |
N/A
(single transaction) |
| e) |
Date of the transaction |
February 17, 2017 |
| f) |
Place of the transaction |
Bats BYX |
|
|
|
|
|
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please
contact:
| Investor
Relations |
|
|
| Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
| Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
| Media |
|
|
| Lisa Adler |
lisa.adler@shire.com |
+1 617
588 8607 |
| Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases. We strive to develop
best-in-class products, many of which are available in more than
100 countries, across core therapeutic areas including Hematology,
Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com